Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
54 results about "Tumour volume" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
High frequency thermal ablation of cancerous tumors and functional targets with image data assistance
InactiveUS6241725B1Ultrasonic/sonic/infrasonic diagnosticsSurgical needlesAbnormal tissue growthTumour volume
This invention relates to the destruction of pathological volumes or target structures such as cancerous tumors or aberrant functional target tissue volumes by direct thermal destruction. In the case of a tumor, the destruction is implemented in one embodiment of the invention by percutaneous insertion of one or more radiofrequency probes into the tumor and raising the temperature of the tumor volume by connection of these probes to a radiofrequency generator outside of the body so that the isotherm of tissue destruction enshrouds the tumor. The ablation isotherm may be predetermined and graded by proper choice of electrode geometry and radiofrequency (rf) power applied to the electrode with or without temperature monitoring of the ablation process. Preplanning of the rf electrode insertion can be done by imaging of the tumor by various imaging modalities and selecting the appropriate electrode tip size and temperature to satisfactorily destroy the tumor volume. Computation of the correct three-dimensional position of the electrode may be done as part of the method, and the planning and control of the process may be done using graphic displays of the imaging data and the rf ablation parameters. Specific electrode geometries with adjustable tip lengths are included in the invention to optimize the electrodes to the predetermined image tumor size.
Owner:COVIDIEN AG
Method and apparatus for selective internal radiation therapy planning and implementation
ActiveUS8738115B2Easy and fast and reliableOptimize successMechanical/radiation/invasive therapiesDrug and medicationsDiagnostic Radiology ModalityTumour volume
Owner:SIEMENS HEALTHCARE GMBH
Tissue biopsy and treatment apparatus and method
InactiveUS20060241577A1Improve clinical outcomesPrecise positioningUltrasound therapySurgical needlesTissue biopsyTumour volume
A method of treating a tumor includes providing a tissue biopsy and treatment apparatus that includes an elongated delivery device that has a lumen and is maneuverable in tissue. A sensor array having a plurality of resilient members is deployable from the elongated delivery device. At least one of the plurality of resilient members is positionable in the elongated delivery device in a compacted state and deployable with curvature into tissue from the elongated delivery device in a deployed state. At least one of the plurality of resilient members includes at least one of a sensor, a tissue piercing distal end or a lumen. The sensor array has a geometric configuration adapted to volumetrically sample tissue at a tissue site to differentiate or identify tissue at the tissue site. At least one energy delivery device is coupled to one of the sensor array, at least one of the plurality of resilient members or the elongated delivery device. The apparatus is then introduced into a target tissue site. The sensor array is then utilized to distinguish a tissue type. The tissue type information derived from the sensor array is utilized to position the energy delivery device to ablate a tumor volume. Energy is then delivered from the energy delivery device to ablate or necrose at least a portion of the tumor volume. The sensor array is then utilized to determine an amount of tumor volume ablation.
Owner:ANGIODYNAMICS INC
Multi-field charged particle cancer therapy method and apparatus
ActiveUS20100090122A1Discharge tube luminescnet screensElectric discharge tubesAbnormal tissue growthBragg peak
The invention relates to treatment of solid cancers. More particularly, the invention relates to a combined rotation / raster method, referred to as multi-field charged particle cancer therapy. The system uses a fixed orientation proton source relative to a rotating patient to yield tumor irradiation from multiple directions. The system combines layer-wise tumor irradiation from many directions with controlled energy proton irradiation to deliver peak proton beam energy within a selected tumor volume or irradiated slice. Optionally, the selected tumor volume for irradiation from a given angle is a distal portion of the tumor. In this manner ingress Bragg peak energy is circumferentially spread about the tumor minimizing damage to healthy tissue and peak proton energy is efficiently, accurately, and precisely delivered to the tumor.
Owner:BALAKIN ANDREY VLADIMIROVICH +1
Method and system for four dimensional intensity modulated radiation therapy for motion compensated treatments
InactiveUS20090041188A1Handling using diaphragms/collimetersCharacter and pattern recognitionAnatomical structuresTumour volume
A deliverable four dimensional (4D) intensity modulated radiation therapy (IMRT) planning method is disclosed, for delivery using a linear accelerator with a dynamic multi-leaf collimator (DMLC). A 4D computed tomography (CT) scan is used for segmenting tumor anatomy on a reference phase of periodic motion of the tumor. Deformable registration of the 4D CT data is used to generate corresponding anatomical structures on other phases. Preferably, the collimator for each beam position is aligned using the gross tumor volume (GTV) centroid motion corresponding to the periodic motion of the tumor, as determined from the two dimensional (2D) projection of a given beam position. A deliverable IMRT plan is created on the 4D CT image set in which the MLC leaf positions and beam on / off status can vary as a function of respiratory phase by solving a four dimensional optimization problem. The mechanical constraints of the MLC leaves are included in the optimization.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Apparatus and method for delivering ablative laser energy and determining the volume of tumor mass destroyed
InactiveUS7171253B2Complete efficientlyEffective destructionBlood flow measurement devicesSurgical needlesTumour volumeVisual monitoring
Owner:NOVIAN HEALTH INC
Method and system for four dimensional intensity modulated radiation therapy for motion compensated treatments
InactiveUS7835493B2Handling using diaphragms/collimetersCharacter and pattern recognitionTumour volumeAnatomical structures
A deliverable four dimensional (4D) intensity modulated radiation therapy (IMRT) planning method is disclosed, for delivery using a linear accelerator with a dynamic multi-leaf collimator (DMLC). A 4D computed tomography (CT) scan is used for segmenting tumor anatomy on a reference phase of periodic motion of the tumor. Deformable registration of the 4D CT data is used to generate corresponding anatomical structures on other phases. Preferably, the collimator for each beam position is aligned using the gross tumor volume (GTV) centroid motion corresponding to the periodic motion of the tumor, as determined from the two dimensional (2D) projection of a given beam position. A deliverable IMRT plan is created on the 4D CT image set in which the MLC leaf positions and beam on / off status can vary as a function of respiratory phase by solving a four dimensional optimization problem. The mechanical constraints of the MLC leaves are included in the optimization.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Application of apatinib and anti-PD-1 antibody combination to preparation of colon cancer medicines
InactiveCN106963948AHigh tumor inhibition rateIncreased area of necrosisOrganic active ingredientsAntibody ingredientsWilms' tumorCancer research
The invention discloses application of apatinib and anti-PD-1 antibody combination to preparation of colon cancer medicines. The colon cancer is treated through combined medication of apatinib and an anti-PD-1 antibody; through experiments, the tumor inhibition rate of apatinib and anti-PD-1 antibody combination is 53.97 percent, the tumor inhibition rate is increased by 40.4 percent as compared with that of a single apatinib group (53.97 percent vs 13.57 percent, P is less than 0.05, Mann-Whitneytest), and the tumor inhibition rate is increased by 23.17 percent as compared with that of a single anti-PD-1 antibody group (53.97 percent vs 13.57 percent, P is less than 0.05, Mann-Whitneytest) (the tumor inhibition rate is equal to 1-expreiment group tumor volume / control group tumor volume). After the apatinib and the anti-PD-1 antibody are combined, the tumor necrosis area can be obviously increased as compared with that of single groups.
Owner:顾艳宏
Imaging method for monitoring delivery of high dose rate brachytherapy
ActiveUS8295910B1Ultrasonic/sonic/infrasonic diagnosticsChiropractic devicesSurgical operationTumour volume
A method for in-situ monitoring both the balloon / cavity and the radioactive source in brachytherapy treatment utilizing using at least one pair of miniature gamma cameras to acquire separate images of: 1) the radioactive source as it is moved in the tumor volume during brachytherapy; and 2) a relatively low intensity radiation source produced by either an injected radiopharmaceutical rendering cancerous tissue visible or from a radioactive solution filling a balloon surgically implanted into the cavity formed by the surgical resection of a tumor.
Owner:JEFFERSON SCI ASSOCS LLC
Imaging apparatus, medical image processing apparatus, and medical image processing method
ActiveCN101513354ABlood flow measurement devicesOrgan movement/changes detectionTumour volumeBlood stream
The invention provides a medial imaging apparatus, ultrasonic imaging apparatus, magnetic resonance imaging apparatus, medical image processing apparatus and medical image processing method. The differential-image creating unit (7) creates a three-dimensional image D4 on which an artery (23) is highlighted and a three-dimensional image D5 on which a tumor (22) is highlighted. An image compositing unit (8) combines the three-dimensional images D4, D5 to composite an image. A display control unit (9) displays the composite image on a monitor (11). Moreover, when compositing an image, the image compositing unit (8) composites the image such that a tumor nutrient blood-flow (24) inside and outside tumor is to be displayed in respective different colors. Furthermore, a blood-flow quantity inside tumor measuring unit calculates a blood-flow quantity inside tumor and a ratio of the blood-flow quantity inside tumor to a tumor volume, and the display control unit (9) displays the blood-flow quantity inside tumor and the ratio of the blood-flow quantity inside tumor to the tumor volume. Accordingly, information that is meaningful for determining malignancy of a tumor can be provided.
Owner:TOSHIBA MEDICAL SYST CORP
Increased T-cell tumor infiltration and eradication of metastases by mutant light
InactiveUS7811983B2Reduce tumor volumeCancer metastasis is reducedVirusesPeptide/protein ingredientsTumour volumeLymphatic Spread
Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and eradication of metastasis using mutant LIGHT are disclosed.
Owner:UNIVERSITY OF CHICAGO
Computer-aided simulation tool for providing assistance in the planning of thermotherapy
The invention relates to a computer-aided simulation tool, in particular to computer-aided simulation methods, for providing assistance in the planning of thermotherapy, and to suitably configured computer equipment. The thermotherapy comprises hyperthermic treatment of a tumour volume within a volume of a human body. The hyperthermic treatment comprises the application of a magnetic field within a treatment volume by means of a magnetic field applicator. In at least one depot volume, thermal energy can be introduced by means of magnetic, paramagnetic and / or superparamagnetic nanoparticles deposited in the body, by power absorption in the applied magnetic field. Field strength values and optionally calculated temperature distributions are provided for assisting the user in the planning of the thermotherapy.
Owner:MAGFORCE AG
Recyclable conformal radioactive particle cabin
PendingCN105727432ATake out the realizationInhibit sheddingX-ray/gamma-ray/particle-irradiation therapyTumour volumeHigh doses
The invention discloses a recyclable conformal radioactive particle cabin which comprises a fixing plate, a guide column and a plurality of moveable partitioning plates, wherein the guide column is longitudinally arranged at the lower end of the fixing plate; the guide column is made of a flexible material; the moveable partitioning plates are overlapped with one another up and down and are arranged on the guide column in a sliding sleeve manner. According to a preoperative plan, under the image guide, a puncture needle is penetrated into a tumor; the tip position is a tail end particle position of the preoperative plan; a needle core is pulled out, the recyclable conformal radioactive particle cabin is placed into a puncture needle tube and pushed to a particle distribution source position specified in the preoperative plan. As the guide column is made of the flexible material, the guide column can have conformal deformation along with change of the tumor, and the recyclable conformal radioactive particle cabin can be taken out after the tumor is eliminated, radioactive particles can be taken out, the consequence that the distribution sources of the radioactive particles in the tumor can be accumulated with one another to generate high-dosage areas along with reduction of the tumor size and radioactive damage of normal tissue around is caused be effectively prevented, and meanwhile particle migration and complication such as lumen obstruction and thromboembolism can be prevented.
Owner:牛洪欣
New applications of tetrahydropalmatine
InactiveCN101773499ALow toxicityExpand the scope of medicinal useOrganic active ingredientsOrganic chemistryTumour volumePharmacy
The invention discloses new applications f tetrahydropalmatine. The new application is an application that tetrahydropalmatine shown in formula I or salts thereof which are acceptable in pharmacy are used to prepare medicines used for inhibiting the proliferation of tumor cells and an application for preparing medicines used for preventing and / or curing tumors. The result of the in vivo experiment using nude mice shows that tetrahydropalmatine can effectively inhibit the growth of tumors, and the tumor volume is much smaller than the volume of the negative control group. Therefore, tetrahydropalmatine which is widely used for analgesia has good antitumor activity, and the result shows that tetrahydropalmatine can be used to prepare medicines for curing cancers, in particular to prepare medicines for curing the lung cancer. The invention broadens the medical application field of tetrahydropalmatine.
Owner:INST OF CHEM CHINESE ACAD OF SCI
Increased T-cell tumor infiltration and eradication of metastases by mutant LIGHT
InactiveUS20090092640A1Reduce tumor volumeCancer metastasis is reducedOrganic active ingredientsVirusesAbnormal tissue growthTumour volume
Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and eradication of metastasis using mutant LIGHT are disclosed.
Owner:UNIVERSITY OF CHICAGO
Oncolytic adenoviruses for treating cancer
PendingUS20190345204A1Reduce pressureLittle resistancePeptide/protein ingredientsGenetic material ingredientsTumour volumeOncolytic adenovirus
Owner:FUNDACIO INST DINVESTIGACIO BIOMEDICA DE BELLVITGE IDIBELL +1
Novel application of fusion protein TAT-DCF1
InactiveCN106913864AReduced activityReduce ratePeptide/protein ingredientsPharmaceutical non-active ingredientsTumour volumeFhit gene
The invention relates to a novel application of fusion protein TAT-DCF1. By judging dcf1-induced U251 cell line apoptosis by virtue of such methods as immuno-electron microscope, atomic force microscope, CCK8 proliferation assay, JC-1 dyeing, nude mouse tumor heterotopic transplantation and the like, results show that dcf1, which is positioned in mitochondria, can cause pathological change of the mitochondria structure and result in drop in membrane potential, so that expression amounts of related genes are changed, and the apoptosis is finally induced. Nude mouse experiments show that them dcf1 can obviously diminish tumor volume of glioma, so that tumor growth is inhibited.
Owner:SHANGHAI UNIV
Tumor puncture path obtaining method, storage medium and electronic equipment
ActiveCN111743626AChoose reasonableAvoid conditions that affect the outcome of surgeryComputer-aided planning/modellingSurgical instruments for coolingTissue architectureTumour volume
The invention discloses a tumor puncture path obtaining method, a storage medium and electronic equipment. The method comprises the following steps of: acquiring body surface data, tumor data and tissue structure data; obtaining a tumor central point according to the tumor data; selecting a needle insertion area from the body surface data according to the tumor data; obtaining a plurality of puncture paths which are not intersected with a tissue structure corresponding to the tissue structure data according to the needle insertion area and the tumor central point; and selecting a target puncture path from the plurality of puncture paths as a tumor puncture path according to the tumor volume in the tumor data, a plurality of ice ball growth durations in the tumor cryoablation operation process in each puncture path, and the volume of an ice ball, the volume of a tumor ice ball covered by the ice ball and the volume of a non-tumor ice ball covered by the ice ball in a non-tumor area corresponding to each ice ball growth duration. Therefore, selection of the tumor puncture path is more reasonable, and the situation that in the prior art, selection of the tumor puncture path is not reasonable, and consequently the operation effect is affected is effectively avoided.
Owner:HYGEA MEDICAL TECH CO LTD
Increased T-cell tumor infiltration by mutant LIGHT
InactiveUS7807784B2Increased rejectAvoid formingVirusesPeptide/protein ingredientsAbnormal tissue growthTumour volume
Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and reduced metastasis using mutant LIGHT are disclosed.
Owner:UNIVERSITY OF CHICAGO
Methods of mouse clinical trial
InactiveUS20200260697A1Compounds screening/testingInorganic active ingredientsTumour volumeTumor Sample
The present disclosure provides methods of conducting and analyzing mouse clinical trials. In one embodiment, the method comprises the steps of receiving a dataset of tumor volumes measured in a mouse clinical trial, determining tumor growth curve of the treatment group and tumor growth curve of the control group; determining area under curve (AUC) of the treatment group and AUC of the control group; and evaluating efficacy of the drug based on an AUC ratio between the AUC of the treatment group and the AUC of the control group, wherein the mouse clinical trial comprises the steps of: obtaining a tumor sample derived from a patient; grafting the tumor sample to a treatment group comprising m mice and a control group comprising n mice, wherein m and n are integers; treating the treatment group with a drug; treating the control group with a vehicle; and measuring tumor volume of the treatment group and tumor volume of the control group at a plurality of days.
Owner:CROWN BIOSCI INC TAICANG
Molecular marker miR-504 for regulating radiation resistance of nasopharyngeal carcinoma
InactiveCN105177112AEasy to operateEasy to sampleMicrobiological testing/measurementTumour volumeNasopharyngeal carcinoma
The invention discloses a molecular marker miR-504 for regulating the radiation resistance of nasopharyngeal carcinoma. Substantial up-regulation of the miR-504 in a nasopharyngeal carcinoma radiation resistance cell line is found, and the miR-504 influences expression of the mitochondrial energy metabolism related molecule TFAM and the oxidative phosphorylation complexes I, III and IV of the downstream of the miR-504 though direct targeting inhibition of NRF1, so the resistance of nasopharyngeal carcinoma cells to radiation is regulated through interfering the mitochondrial energy metabolism. The expression level of the miR-504 in serum of a nasopharyngeal carcinoma radiotherapy patient is positively correlated with the total tumor volume, so the miR-504 provides a new detection index for radiotherapy reaction control in the radiotherapy process of the nasopharyngeal carcinoma patient, and provides a new target for nasopharyngeal carcinoma radiotherapy.
Owner:CENT SOUTH UNIV
Oncolytic adenoviruses for treating cancer
ActiveUS10316065B2Reduce pressureLittle resistanceBiocidePeptide/protein ingredientsTumour volumeOncolytic adenovirus
The invention is related to an oncolytic adenovirus that comprises a sequence encoding a hyaluronidase enzyme inserted in its genome. This adenovirus spreads more efficiently in the tumour mass and therefore the oncolytic effect is increased. Injecting the oncolytic adenovirus of the invention endovenously results in tumour volume regressions. Therefore, the oncolytic adenovirus of the present invention is useful for the treatment of a cancer or a pre-malignant state of cancer.
Owner:FUNDACIO INST DINVESTIGACIO BIOMEDICA DE BELLVITGE IDIBELL +1
Tumor immunotherapy target aiming at tumor-associated macrophages
ActiveCN108014327APromote formationAvoid interactionOrganic active ingredientsPeptide/protein ingredientsAbnormal tissue growthTumour volume
The present invention discloses a tumor immunotherapy target aiming at tumor-associated macrophages. Experiments prove that LSECtin, BTN3A2 and BNT3A3 can promote tumor progression by promoting of thestemness maintenance of tumor cells, more specifically, formation of tumor cell spheres, expression of stem transcription factors and tumor progression in a mice tumor model are promoted; by inhibition of interaction of the LSECtin with the BTN3A2 and the BTN3A3, the tumor progression can be effectively slowed down, more specifically, the incidence of tumors is reduced, and tumor volume growth can be slowed down.
Owner:INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA +1
Compositions and methods for enhancing cancer radiotherapy
ActiveUS10905723B2Reduce volumeReduce weightSulfur/selenium/tellurium inorganic active ingredientsFish material medical ingredientsTumour volumeSide effect
A nutritional supplement containing fish oil and selenium has been identified that potentiates radiotherapy of tumors in a synergistic fashion. Cotherapy with such a supplement and radiotherapy results in substantially improved reductions in tumor volume of animal models relative to radiotherapy alone, and reduces common side effects such as weight loss, inflammation, and damage to the gastrointestinal tract. Such cotherapy was also found to reduce the incidence of metastasis from the primary implantation site, and to modulate expression of genes associated with apoptosis in tumor cells. A formulation for such a supplement that is both well tolerated and palatable is also provided.
Owner:HSIA HOUN SIMON
Mid-plane range-probing techniques for particle therapy
ActiveUS20190076673A1Accurate measurementReduce the possibilityX-ray/gamma-ray/particle-irradiation therapyTumour volumeIn vivo
Systems, methods, and computer-readable storage media providing techniques for probing in-vivo beam ranges directly using therapeutic beams for particle therapy treatment are disclosed. In an embodiment, a configuration is determined for one or more probing spots, each spot corresponding to a planned location within an interior region of a tumor volume where a dose of radiation is to be delivered. At least one therapeutic beam is provided to the tumor volume, and one or more images may be captured to provide an indication of the range / depth of the probing spots. Providing the probing spots to the interior of the tumor volume reduces the risk that the dose is provided to sensitive tissue (e.g., because even if the dose is delivered to a location other than the planned location, the dose is likely to remain contained within the tumor volume).
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Preparation method of bispecific antibody NK cells, and cells and application thereof
PendingCN111826400AExcellent cell phenotypeHigh purityNucleic acid vectorBlood/immune system cellsTumour volumeCancer cell
The invention provides a preparation method of bispecific antibody NK cells, and cells and application thereof. The method comprises the following steps of: culturing NK cells, constructing a CD16A / HSP70 bispecific antibody lentiviral expression vector, and infecting the NK cells by the CD16A / HSP70 bispecific antibody lentiviral expression vector so as to obtain the bispecific antibody NK cells ofa CD16A / HSP70 antibody. The NK cells prepared by the invention are excellent in cell-specific phenotype and high in purity, wherein CD3-CD56+ achieves 97.13%; CD3-CD56+CD16+ achieves 93%; and the NKcells carrying the CD16A / HSP70 bispecific antibody lentiviral expression vector can effectively eliminate liver cancer cells and inhibit increasing of the tumour volume of the liver cancer.
Owner:中科宝承生物医学科技有限公司
Method for detecting a solid tumor cancer
ActiveUS10451626B2Improve abilitiesReduce riskTherapiesMicrobiological testing/measurementTumour volumeBiologic marker
Owner:PHADIA AB
Evaluation of Radiation Dose Tolerance Limits
InactiveUS20110285716A1Drawing from basic elementsMechanical/radiation/invasive therapiesAnatomical structuresTumour volume
A software device that aids the user to evaluate the dose distribution and dose tolerance limits for radiation therapy treatment plans. Radiation therapy treats a desired tumor volume as well as undesired volumes of critical anatomical structures within the patient. The dose volume histogram (DVH) is commonly used to assess the volume of tumor and the volumes of critical structures receiving certain doses. The disclosed invention overlays historical dose statistical information on the dose volume histogram to conveniently enable the user to evaluate the quality of the radiation treatment plan.
Owner:GRIMM JIMM
Method and Apparatus for Measuring Volume of Subcutaneous Tumors
InactiveUS20130096465A1Accurate and efficient measurementPerson identificationSensorsTumour volumeFungating tumour
Owner:RUTGERS THE STATE UNIV
Establishment and applications of human pituitary adenoma cell line
InactiveCN107460170AFast growthStable passageOther foreign material introduction processesTumor/cancer cellsTumour volumePhysiology
The invention relates to a method for preparing a human pituitary adenoma cell line, the human pituitary adenoma cell line obtained through the method, and applications of the human pituitary adenoma cell line in medicine research and development. The method comprises the following steps: (a) transplanting the human pituitary adenoma to a non-human animal suffering from immune deficiency; (b) when the weight of the transplanted pituitary adenoma achieves 15% or above of the body weight of the non-human animal or when the size of the transplanted tumor does not increase, taking out the pituitary adenoma, and transplanting the pituitary adenoma into the new non-human animal suffering from immune deficiency; (c) repeating the step (b), when the Ki67 positive expression ratio of the pituitary adenoma cells is 20% or above, taking out the pituitary adenoma; and (d) culturing the pituitary adenoma cells which are taken out, thus obtaining the pituitary adenoma cell line.
Owner:任远 +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com